Europe buys 160 million doses of Moderna vaccine

25 November 2020

Messenger RNA specialist Moderna (Nasdaq: MRNA) has agreed to supply 80 million doses of its COVID-19 vaccine to the European Commission, with an option for a further 80 million.

The US biotech recently announced that the Phase III trial of the candidate, mRNA-1273, met its efficacy goal at the first interim analysis, with overall vaccine efficacy of 94.5%.

Safety data were also highly encouraging, and the firm is working with governments around the world to secure regulatory approvals and supply agreements.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK